A “Catastrophic” Heparin-Induced Thrombocytopenia
Authors:
Open Access
- 13 April 2020
- journal article
- case report
- Published by Wiley in Case Reports in Medicine
- Vol. 2020, 1-3
Abstract
Background. Heparin-induced thrombocytopenia (HIT) is a transient, antibody-mediated thrombocytopenia syndrome that usually follows exposure to unfractioned heparin (UFH) or low-molecular-weight heparin (LMWH). In contrast to other pathological conditions which lead to thrombocytopenia and bleeding complications, HIT results in a paradoxical prothrombotic state. It is caused by antibodies directed to complexes containing UFH or LMWH and a self-platelet protein: the platelet factor 4 (PF4). The heparin-PF4 immune complex leads to activation of platelets, monocytes, and endothelial cells which release procoagulant proteins and tissue factor with subsequent blood coagulation activation. Case Report. We describe the case of a woman undergone to knee replacement and affected by urosepsis who developed a HIT after exposure to enoxaparin. The thrombotic burden was very impressive involving the arterial and venous cerebral vessel and the venous pulmonary, hepatic, and inferior legs vascular beds. The patient was successfully treated with fondaparinux without recurrent thrombosis or bleeding. The clinical scenario could be named “catastrophic HIT” like the catastrophic antiphospholipid syndrome since they have a similar pathogenetic mechanism involving both platelets and monocytes procoagulant activities and a similar clinical manifestation with a life-threatening multiple arterial and/or venous thromboses. Conclusion. Patients presenting with HIT could show a very impressive thrombotic burden resembling to that of the catastrophic antiphospholipid syndrome. A careful differential diagnosis should be made towards other pathological conditions which lead to thrombocytopenia to avoid an unnecessary and potentially harmful platelet transfusion. Although fondaparinux is off-label, its use in patients with HIT is simple and seems to be effective.Keywords
This publication has 13 references indexed in Scilit:
- Anti-PF4/heparin antibodies are increased in hospitalized patients with bacterial sepsisThrombosis Research, 2018
- Platelet transfusions in platelet consumptive disorders are associated with arterial thrombosis and in-hospital mortalityBlood, 2015
- Nonheparin Anticoagulants for Heparin-Induced ThrombocytopeniaNew England Journal of Medicine, 2013
- Platelet factor 4 binding to lipid A of Gram-negative bacteria exposes PF4/heparin-like epitopesBlood, 2012
- A Spontaneous Prothrombotic Disorder Resembling Heparin-induced ThrombocytopeniaThe American Journal of Medicine, 2008
- Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin‐induced thrombocytopenia in two clinical settingsJournal of Thrombosis and Haemostasis, 2006
- Thrombocytopenic conditions—autoimmunity and hypercoagulability: Commonalities and differences in ITP, TTP, HIT, and APSAmerican Journal of Hematology, 2005
- Clinical features of heparin-induced thrombocytopenia including risk factors for thrombosisThrombosis and Haemostasis, 2005
- Heparin-induced thrombocytopeniaAnnals of Hematology, 1989
- Arterial Embolism Occurring During Systemic Heparin TherapyArchives of Surgery, 1958